Vinorelbine + mitomycin C as second-line treatment of metastatic breast cancer

A two-stage phase 2 study

S. De Placido, R. Lauria, F. Perrone, A. Vernaglia Lombardi, C. Carlomagno, E. Varriale, R. Costanzo, L. Leo, M. De Laurentiis, A. R. Bianco

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Second-line treatment of patients with metastatic breast cancer resistant to anthracyclines is an important clinical issue. The aim of the present two-stage phase II study was to evaluate activity and toxicity of vinorelbine + mitomycin C (VM) in such patients. Fifty-five patients were entered and received vinorelbine 30 mg/m2 on days 1 and 8 + mitomycin C 10 mg/m2 on day 1, every 4 weeks, up to 9 cycles. Two complete and 23 partial responses were observed for an overall response rate of 45.4% (95% CI 32.0-59.4). Median survival was 13 months and probability of surviving after a 1-year follow-up was 58%. Toxicity was never life-threatening, but G-CSF was used in 45% of cycles to contrast neutropenia that was the most frequent side effect. These results are consistent with previous studies and strongly support VM being considered among the optimal polychemotherapy regimens for second-line treatment of metastatic breast cancer in clinical practice; for clinical research aims, VM should be used as control arm for randomized trials evaluating the activity of new drugs against breast cancer.

Original languageEnglish
Pages (from-to)8-14
Number of pages7
JournalOncology
Volume58
Issue number1
Publication statusPublished - 2000

Fingerprint

Mitomycin
Breast Neoplasms
Anthracyclines
Granulocyte Colony-Stimulating Factor
Therapeutics
Combination Drug Therapy
Neutropenia
Survival
vinorelbine
Research
Pharmaceutical Preparations

Keywords

  • Metastatic breast cancer
  • Mitomycin C
  • Phase 2 study
  • Second-line chemotherapy
  • Vinorelbine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

De Placido, S., Lauria, R., Perrone, F., Vernaglia Lombardi, A., Carlomagno, C., Varriale, E., ... Bianco, A. R. (2000). Vinorelbine + mitomycin C as second-line treatment of metastatic breast cancer: A two-stage phase 2 study. Oncology, 58(1), 8-14.

Vinorelbine + mitomycin C as second-line treatment of metastatic breast cancer : A two-stage phase 2 study. / De Placido, S.; Lauria, R.; Perrone, F.; Vernaglia Lombardi, A.; Carlomagno, C.; Varriale, E.; Costanzo, R.; Leo, L.; De Laurentiis, M.; Bianco, A. R.

In: Oncology, Vol. 58, No. 1, 2000, p. 8-14.

Research output: Contribution to journalArticle

De Placido, S, Lauria, R, Perrone, F, Vernaglia Lombardi, A, Carlomagno, C, Varriale, E, Costanzo, R, Leo, L, De Laurentiis, M & Bianco, AR 2000, 'Vinorelbine + mitomycin C as second-line treatment of metastatic breast cancer: A two-stage phase 2 study', Oncology, vol. 58, no. 1, pp. 8-14.
De Placido S, Lauria R, Perrone F, Vernaglia Lombardi A, Carlomagno C, Varriale E et al. Vinorelbine + mitomycin C as second-line treatment of metastatic breast cancer: A two-stage phase 2 study. Oncology. 2000;58(1):8-14.
De Placido, S. ; Lauria, R. ; Perrone, F. ; Vernaglia Lombardi, A. ; Carlomagno, C. ; Varriale, E. ; Costanzo, R. ; Leo, L. ; De Laurentiis, M. ; Bianco, A. R. / Vinorelbine + mitomycin C as second-line treatment of metastatic breast cancer : A two-stage phase 2 study. In: Oncology. 2000 ; Vol. 58, No. 1. pp. 8-14.
@article{4625ddc6263649df8999161bf86e5dc9,
title = "Vinorelbine + mitomycin C as second-line treatment of metastatic breast cancer: A two-stage phase 2 study",
abstract = "Second-line treatment of patients with metastatic breast cancer resistant to anthracyclines is an important clinical issue. The aim of the present two-stage phase II study was to evaluate activity and toxicity of vinorelbine + mitomycin C (VM) in such patients. Fifty-five patients were entered and received vinorelbine 30 mg/m2 on days 1 and 8 + mitomycin C 10 mg/m2 on day 1, every 4 weeks, up to 9 cycles. Two complete and 23 partial responses were observed for an overall response rate of 45.4{\%} (95{\%} CI 32.0-59.4). Median survival was 13 months and probability of surviving after a 1-year follow-up was 58{\%}. Toxicity was never life-threatening, but G-CSF was used in 45{\%} of cycles to contrast neutropenia that was the most frequent side effect. These results are consistent with previous studies and strongly support VM being considered among the optimal polychemotherapy regimens for second-line treatment of metastatic breast cancer in clinical practice; for clinical research aims, VM should be used as control arm for randomized trials evaluating the activity of new drugs against breast cancer.",
keywords = "Metastatic breast cancer, Mitomycin C, Phase 2 study, Second-line chemotherapy, Vinorelbine",
author = "{De Placido}, S. and R. Lauria and F. Perrone and {Vernaglia Lombardi}, A. and C. Carlomagno and E. Varriale and R. Costanzo and L. Leo and {De Laurentiis}, M. and Bianco, {A. R.}",
year = "2000",
language = "English",
volume = "58",
pages = "8--14",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "1",

}

TY - JOUR

T1 - Vinorelbine + mitomycin C as second-line treatment of metastatic breast cancer

T2 - A two-stage phase 2 study

AU - De Placido, S.

AU - Lauria, R.

AU - Perrone, F.

AU - Vernaglia Lombardi, A.

AU - Carlomagno, C.

AU - Varriale, E.

AU - Costanzo, R.

AU - Leo, L.

AU - De Laurentiis, M.

AU - Bianco, A. R.

PY - 2000

Y1 - 2000

N2 - Second-line treatment of patients with metastatic breast cancer resistant to anthracyclines is an important clinical issue. The aim of the present two-stage phase II study was to evaluate activity and toxicity of vinorelbine + mitomycin C (VM) in such patients. Fifty-five patients were entered and received vinorelbine 30 mg/m2 on days 1 and 8 + mitomycin C 10 mg/m2 on day 1, every 4 weeks, up to 9 cycles. Two complete and 23 partial responses were observed for an overall response rate of 45.4% (95% CI 32.0-59.4). Median survival was 13 months and probability of surviving after a 1-year follow-up was 58%. Toxicity was never life-threatening, but G-CSF was used in 45% of cycles to contrast neutropenia that was the most frequent side effect. These results are consistent with previous studies and strongly support VM being considered among the optimal polychemotherapy regimens for second-line treatment of metastatic breast cancer in clinical practice; for clinical research aims, VM should be used as control arm for randomized trials evaluating the activity of new drugs against breast cancer.

AB - Second-line treatment of patients with metastatic breast cancer resistant to anthracyclines is an important clinical issue. The aim of the present two-stage phase II study was to evaluate activity and toxicity of vinorelbine + mitomycin C (VM) in such patients. Fifty-five patients were entered and received vinorelbine 30 mg/m2 on days 1 and 8 + mitomycin C 10 mg/m2 on day 1, every 4 weeks, up to 9 cycles. Two complete and 23 partial responses were observed for an overall response rate of 45.4% (95% CI 32.0-59.4). Median survival was 13 months and probability of surviving after a 1-year follow-up was 58%. Toxicity was never life-threatening, but G-CSF was used in 45% of cycles to contrast neutropenia that was the most frequent side effect. These results are consistent with previous studies and strongly support VM being considered among the optimal polychemotherapy regimens for second-line treatment of metastatic breast cancer in clinical practice; for clinical research aims, VM should be used as control arm for randomized trials evaluating the activity of new drugs against breast cancer.

KW - Metastatic breast cancer

KW - Mitomycin C

KW - Phase 2 study

KW - Second-line chemotherapy

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=17444444679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17444444679&partnerID=8YFLogxK

M3 - Article

VL - 58

SP - 8

EP - 14

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 1

ER -